¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high osmolar contrast agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high frequency filter
    °íÁÖÆÄ¿©°ú±â, °íÁ֯İŏ£°³
  • high frequency recombination
    °íºóµµÀçÁ¶ÇÕ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ¿ëÇØ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high insertion
    °íÀ§ºÎÂø
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • high pelvic position
    ³ôÀº°ñ¹ÝÀÚ¼¼
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high potency
    1. °íÈ¿´É, °í¿ª°¡ 2. °íÀáÀç·Â
  • high power application
    °íÃâ·ÂÀû¿ë
  • high residue diet
    °íÀÜ·ùÀ½½Ä
  • high resolution
    °íÇØ»óµµ
  • high resolution computed tomography
    °íÇØ»óÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(¼ú)
  • high risk group
    °íÀ§Ç豺
  • high risk patient
    °íÀ§ÇèȯÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high forceps
    °íÀ§Áý°Ô, À§ÂÊÁý°Ô
  • high frequency filter
    °íÁ֯İŏ£°³, °íÁÖÆÄ¿©°ú
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • high-output heart failure
    °í¹ÚÃâ½ÉÀå±â´É»ó½Ç, °í¹ÚÃâ½ÉÀåºÎÀü
  • high-pass filter
    °íÁÖÆÄÅë°ú°Å¸£°³, °íÁÖÆÄÅë°úÇÊÅÍ
  • high risk group
    °íÀ§Çèµµ±º
  • high insertion
    °íÀ§ºÎÂø
  • high resolution
    °íÇØ»ó
  • high signal
    °í½ÅÈ£
  • high speed
    °í¼Ó, °í¼Óµµ
  • high altitude polycythemia
    ³ôÀº°÷ÀûÇ÷±¸Áõ°¡Áõ
  • high dose rate
    °í¼±·®·ü
  • high dose rate intraluminal radiotherapy
    °í¼±·®À²°ü³»¹æ»ç¼±Ä¡·á
  • high energy radiation
    °í¿¡³ÊÁö¹æ»ç¼±
  • high field magnetic resonance scanner
    °íÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antifungal agent
    Ç×Áø±Õ¾à, Ç×Áø±Õ¹°Áú, Ç×Áø±ÕÀÎÀÚ.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antiinflammatory agent
    ¼Ò¿°Á¦
  • antimicrobial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ).
  • antimicrobial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ).
  • antimycotic agent
    Ç×Áø±Õ¾à(ù÷òØÐ¶å·).
  • antineoplastic agent
    Ç×Á¾¾çÁ¦.
  • antineoplastic agent
    Ç×Á¾¾ç¼º¹°Áú
  • antiparasympathetic agent
    Ç׺α³°¨½Å°æ(¼º)¾à(ù÷ÜùÎßÊïãêÌè(àõ)å·£©.
  • antiplatelet agent
    Ç×Ç÷¼ÒÆÇÁ¦(ù÷úìá³÷ùð¥).
  • antituberculous agent
    Ç×°áÇÙ¾à(ù÷Ì¿ú·å·).
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
  • antitumor agent
    Ç׾Ͼà(ù÷äßå·), Ç×Á¾¾ç(¼º)¾à.
  • antitumor agent
    Ç׾Ͼà(ù÷ å·), Á¦¾Ï¾à(ð¤ å·), Ç×Á¾¾ç(¼º)¾à(ù÷ðþåËàõå·), Ç×Á¾¾ç(¼º)ÀÎÀÚ.
  • antiviral agent
    Ç×¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½º¹°Áú, Ç×¹ÙÀÌ·¯½ºÀÎÀÚ, Ç×¹ÙÀÌ·¯½ºÁ¦Á¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • positive contrast medium
    ¾ç¼º Á¶¿µÁ¦
  • pre contrast enhanced image
    Á¶¿µ Áõ°¡Àü ¿µ»ó
  • proton density contrast
    ¾çÀÚ ¹Ðµµ ´ëÁ¶
  • simultaneous contrast
    µ¿½Ã(¼º) ´ëºñ (¡­ÓßÝï).
  • successive contrast
    ¹Ýº¹´ëºñ(¡­ÓßÝï).
  • taste contrast
    ¹Ì´ëºñ(Ú«ÓßÝï).
  • tissue contrast
    Á¶Á÷ ´ëÁ¶µµ
  • water soluble contrast media
    ¼ö¿ë¼º Á¶¿µÁ¦
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • lympholytic agent
    ¸²ÇÁ±¸¿ëÇØÁ¦(éÁú°ð­)
  • lysosomotropic agent
    ¶óÀ̼ÒÁ»ÀÚ±ØÁ¦(í©Ð»ð¥)
  • methylating agent
    ¸ÞƿȭÁ¦(ð¥)
  • mutagenic agent
    º¯ÀÌ¿øÁ¦(ܨì¶ê«ð¥)
  • oxidizing agent
    »êÈ­Á¦(ß«ûùð¥)
  • precipitating agent
    ħ°­Á¦(öØË½ð¥)
  • pressor agent
    Ç÷¾Ð»ó½ÂÁ¦(úìäâß¾ã°ð¥)
  • reducing agent
    ȯ¿ø ½Ã¾à(ü½êªãËå·)
  • sequestering agent
    °ÝÀýÇü¼ºÁ¦(̰ï¾û¡à÷ð¥)
  • sulfating agent
    Ȳ»êÈ­Á¦ (üÜß«ûùð¥)
  • surface-active agent
    Ç¥¸éȰ¼ºÁ¦ (øúØüüÀàõð¥)
  • transport agent
    ¼ö¼ÛÁ¦(âÃáêð¥)
  • uncoupling agent
    ¦Ǯ±âÁ¦(ð¥)
  • wetting agent
    ½ÀÆ÷Á¦(ã¥øÖð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • super high field MR scanner
    ÃʰíÀÚÀåMR½ºÄ³³Ê, ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • ultra high field MR scanner
    ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • 3D phase contrast angiography
    3Â÷¿øÀ§»ó´ëÁ¶ Ç÷°üÃÔ¿µ¼ú
  • barium contrast medium
    ¹Ù·ýÁ¶¿µÁ¦
  • blood oxygenation level dependant contrast
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸´ëÁ¶µµ
  • CE [=contrast enhancement]
    Á¶¿µÁõ°­
  • CE FAST [=contrast enhanced fast acquisition in the steady state]
    Ç×Á¤»óÅÂÀÇ ´ëÁ¶µµÁõ°­°í¼Óȹµæ
  • contrast
    ´ëÁ¶, ´ëºñ, Á¶¿µ
  • contrast enema
    Á¶¿µ°üÀå
  • contrast enhancement [=CE]
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • contrast material
    Á¶¿µ ¹°Áú, Á¶¿µÁ¦
  • contrast medium
    Á¶¿µÁ¦
  • contrast to noise ratio
    ´ëÁ¶ÀâÀ½ºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HFT high-frequency transduction; high-frequency transfer
HIHA high impulsiveness, high anxiety
HPF heparin-precipitable fraction; hepatic plasma flow; high-pass filter; high-power field [microscope];...
HRP high-risk patient; high-risk pregnancy; histidine-rich protein; horseradish peroxidase
HV hallux valgus; Hantaan virus; heart volume; hepatic vein; herpesvirus; high voltage; high volume; ho...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CM Contrast media
CM Contrast medium
CV Contrast venography
CD Contrast-detail
CE-CT Contrast-enhanced computed tomography
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high signal intensity
    °í½ÅÈ£ °­µµ
  • high speed core cut biopsy
    °í¼Ó Á᫐ »ý°Ë
  • high surface
    °íÇ¥¸é
  • high threshold mechanical nociceptor
    °í¿ªÄ¡ ±â°è Ä§ÇØ¼ö¿ëü, °í¿ªÄ¡ ±â°è À¯Çؼö¿ë±â
  • high vacuum
    °íÁø°ø
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • high voltage radiography
    °í¾Ð ¹æ»ç¼± ÃÔ¿µ¼ú, °í¾Ð ÃÔ¿µ¼ú, °íÀü¾Ð ÃÔ¿µ¼ú
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • high-density lipoprotein
    °í¹Ðµµ Áö¹æ ´Ü¹é
  • high-energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÌ °áÇÕÀº ¾Æµ¥³ë½Å »ïÀλê, Æ÷½ºÆ÷Å©·¹¾ÆÆ¾, ´ç´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high-energy sulfer bond
    °í¿¡³ÊÁö À¯È² °áÇÕ
    ÀÌ °áÇÕ¿¡¼­ °¡Àå Áß¿äÇÑ °ÍÀº ¾Æ¼¼Æ¿ CoA¿¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î¼­ Áö¹æ»ê »ýÇÕ¼ºÀÇ ÁÖ¿ä ¿¡³ÊÁö¿øÀÌ µÈ´Ù.
  • high-frequency oscillation
    °íÁÖÆÄ Áøµ¿
  • high-power interaction
    °íÃâ·Â »óÈ£ ÀÛ¿ë
  • high-speed grinding
    °í¼Ó »èÁ¦
    ºü¸¥ ¼Óµµ·Î °¥¾Æ³»´Â °Í.
  • high-threshold class
    °í¿ªÄ¡±º
    ¿ªÄ¡ÀÇ Å©±â°¡ ³ôÀº Áý´Ü.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
antinematodal agent Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.
(12 Dec 1998)
antineoplastic agent Agents inhibiting or preventing the growth of neoplasms, checking the maturation and proliferation of malignant cells.
(12 Dec 1998)
antineoplastic agent, alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumour efficacy and the presence in their chemical structures of n-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumour cells are not completely understood.
(12 Dec 1998)
antineoplastic agent, combined The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
(12 Dec 1998)
antineoplastic agent, hormonal Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias.
(12 Dec 1998)
antineoplastic agent, phytogenic Agents, obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
(12 Dec 1998)
antipsychotic agent A functional category of neuroleptic drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders (e.g., chlorpromazine, haloperidol).
See: neuroleptic.
Synonym: antipsychotic, major tranquilliser.
(05 Mar 2000)
antithyroid agent <pharmacology> Medications which suppress thyroid function.
Examples include methimazole and propylthiouracil.
(13 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high-tone
    °¡¶ôÀÌ ³ôÀº
  • high-toned
    °¡¶ôÀÌ ³ôÀº
  • High Dutch
    =High German
  • High Street
    Å«(¹øÈ­ÇÑ) °Å¸®
  • Lord High Chancellor
    ´ë¹ý°ü
  • Middle High German
    Áß¼¼(Áß±â) °íÁö µ¶ÀϾî(12-15¼¼±â)
  • Old High German
    =GERMAN
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • extremely high frequency
    (Åë½Å)ÃʰíÁÖÆÄ
  • high
    ³ôÀº;...ÀÇ ³ôÀÌÀÇ;³ôÀº °÷(À¸·ÎºÎÅÍ)ÀÇ;°íÁöÀÇ;°í±Í(°í»ó,¼þ°í)ÇÑ;°í¿øÀÇ;°íÀ§ÀÇ;°í±ÞÀÇ;°ªºñ½Ñ;°Ý·ÄÇÑ;±ØµµÀÇ;°ú°ÝÇÑ;£Àº
  • high
    (¿¬°áÇü)(~³ôÀÌÀÇ)ÀÇ ¶æ
  • high Church
    °í±³È¸ÆÄ(¿µ±¹ ±³È¸ÆÄ Áß,±³È¸ÀÇ ±³ÀÇ ¹× ÀǽÄÀ» Á¸ÁßÇÏ´Â ÇÑÆÄ)
  • high Churchman
    °í±³È¸ÆÄ ½Åµµ
  • high Court
    °íµî¹ý¿ø
  • high German
    GERMAN
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á